Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

被引：0
|
作者：
Wallace, Daniel J. [1 ]
Furie, Richard [2 ]
Tanaka, Yoshiya [3 ]
Kalunian, Kenneth C. [4 ]
Mosca, Marta [5 ]
Petri, Michelle [6 ]
Dorner, Thomas [7 ,8 ]
Cardiel, Mario H. [9 ]
Bruce, Ian N. [10 ]
Gomez, Elisa [11 ]
DeLozier, Amy M. [11 ]
Janes, Jonathan [11 ]
Linnik, Matthew D. [11 ]
de Bono, Stephanie [11 ]
Silk, Maria E. [11 ]
Hoffman, Robert W. [11 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Cedars Sinai Med Ctr, Los Angeles, CA 90095 USA
[2] Zucker Sch Med Hofstra Northwell, Div Rheumatol, Great Neck, NY USA
[3] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka, Japan
[4] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[5] Univ Pisa, Pisa, Italy
[6] Johns Hopkins Univ, Sch Med, Med Rheumatol, Baltimore, MD USA
[7] Charite Univ Med Berlin, Berlin, Germany
[8] Deutsch Rheumaforschungszentrum DRFZ, Berlin, Germany
[9] Ctr Invest Clin Morelia SC, Morelia, Michoacan, Mexico
[10] Univ Manchester, Div Musculoskeletal & Dermatol Sci, Ctr Musculoskeletal Res, Manchester, Lancs, England
[11] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
970
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)
    Morand, Eric F.
    Vital, Edward M.
    Petri, Michelle
    van Vollenhoven, Ronald
    Wallace, Daniel J.
    Mosca, Marta
    Furie, Richard A.
    Silk, Maria E.
    Dickson, Christina L.
    Meszaros, Gabriella
    Jia, Bochao
    Crowe, Brenda
    Torre, Inmaculada de la
    Doerner, Thomas
    LANCET, 2023, 401 (10381): : 1001 - 1010
  • [22] Omega-3 in Systemic Lupus Erythematosus: A Double-Blind, Placebo-Controlled Randomized Clinical Trial In Systemic Lupus Erythematosus
    Bello, Kayode J.
    Fang, Hong
    Magder, Laurence S.
    Petri, Michelle
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S963 - S963
  • [23] A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus Erythematosus
    Wallace, Daniel J.
    Stohl, William
    Furie, Richard A.
    Lisse, Jeffrey R.
    McKay, James D.
    Merrill, Joan T.
    Petri, Michelle A.
    Ginzler, Ellen M.
    Chatham, W. Winn
    McCune, W. Joseph
    Fernandez, Vivian
    Chevrier, Marc R.
    Zhong, Z. John
    Freimuth, William W.
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2009, 61 (09): : 1168 - 1178
  • [24] GLANCE Results of a phase 2, randomized, double-blind, placebo-controlled study
    Goodman, A. D.
    Rossman, H.
    Bar-Or, A.
    Miller, A.
    Miller, D. H.
    Schmierer, K.
    Lublin, F.
    Khan, O.
    Bormann, N. M.
    Yang, M.
    Panzara, M. A.
    Sandrock, A. W.
    NEUROLOGY, 2009, 72 (09) : 806 - 812
  • [25] Results from PIONEER: a randomized, double-blind, placebo-controlled, phase 2 study of avapritinib in patients with indolent systemic mastocytosis
    Radia, Deepti H.
    Sabato, Vito
    Castells, Mariana
    Akin, Cem
    Elberink, Hanneke Oude
    Tashi, Tsewang
    George, Tracy I.
    Roche, Maria
    DeAngelo, Daniel J.
    Gotlib, Jason
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 8 - 9
  • [26] Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial
    Wu, Di
    Li, Jing
    Xu, Dong
    Merrill, Joan T.
    van Vollenhoven, Ronald F.
    Liu, Yi
    Hu, Jiankang
    Li, Yang
    Li, Fen
    Huang, Chenghui
    Wang, Guochun
    Li, Xiaomei
    Zhao, Jianhong
    Zhao, Dongbao
    Huang, Cibo
    Liu, Huaxiang
    Wei, Wei
    Shi, Guixiu
    Lu, Fuai
    Zuo, Xiaoxia
    Bi, Liqi
    Li, Zhijun
    Wang, Xiaoxia
    Zhang, Miaojia
    Tie, Ning
    Li, Juan
    Mo, Hanyou
    Fang, Jianmin
    Bao, Chunde
    Zhang, Fengchun
    ANNALS OF THE RHEUMATIC DISEASES, 2024, 83 (04) : 475 - 487
  • [27] Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
    Morand, Eric
    Pike, Marilyn
    Merrill, Joan T.
    van Vollenhoven, Ronald
    Werth, Victoria P.
    Hobar, Coburn
    Delev, Nikolay
    Shah, Vaishali
    Sharkey, Brian
    Wegman, Thomas
    Catlett, Ian
    Banerjee, Subhashis
    Singhal, Shalabh
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 (02) : 242 - 252
  • [28] EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL
    Hassanien, M.
    Moshrif, A.
    Hetta, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 34 - 35
  • [29] Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study
    Werth, Victoria P.
    Fleischmann, Roy
    Robern, Michael
    Touma, Zahi
    Tiamiyu, Iyabode
    Gurtovaya, Oksana
    Pechonkina, Alena
    Mozaffarian, Afsaneh
    Downie, Bryan
    Matzkies, Franziska
    Wallace, Daniel
    RHEUMATOLOGY, 2022, 61 (06) : 2413 - 2423
  • [30] Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study
    Furie, Richard A.
    Hough, Douglas R.
    Gaudy, Allison
    Ye, Ying
    Korish, Shimon
    Delev, Nikolay
    Weiswasser, Michael
    Zhan, Xiaojiang
    Schafer, Peter H.
    Werth, Victoria P.
    LUPUS SCIENCE & MEDICINE, 2022, 9 (01):
12345